Personal Care R&D In Brief

Probio mouthrinse for sale, license: Positive clinical trial results for Oragenics' Probiora3 probiotic mouthrinse position the firm to sell or license its technology, allowing it to focus on other R&D opportunities, specifically its MU1140 antibiotic candidate currently under development, the firm states Nov. 15. Probiora3 effectively reduces levels of disease-causing oral bacteria in young, healthy adult subjects, showing reductions in Streptococcus mutans, a teeth-decaying bacterium, and two bacterial strains linked to gum diseases in subjects using the product for one week, the Alachua, Fla.-based company says. "The oral probiotic represents a breakthrough approach to maintaining oral health by utilizing cultures of bacteria commonly found in healthy mouths to provide a natural defense against those bacteria thought to be harmful to teeth and gums," according to Oragenics' Scientific Advisory Committee Chairman Raman Bedi, DDS...